Correspondence on “Associations of baseline use of biologic or targeted synthetic DMARDs with COVID-19 severity in rheumatoid arthritis: results from the COVID-19 global rheumatology alliance physician registry”

Detalles Bibliográficos
Autores principales: van Vollenhoven, Ronald F, Tas, Sander W, Nurmohamed, Michael T
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2023
Materias:
Correspondence
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10359557/
https://www.ncbi.nlm.nih.gov/pubmed/34389606
http://dx.doi.org/10.1136/annrheumdis-2021-221146
_version_ 1785075910136823808
author van Vollenhoven, Ronald F
Tas, Sander W
Nurmohamed, Michael T
author_facet van Vollenhoven, Ronald F
Tas, Sander W
Nurmohamed, Michael T
author_sort van Vollenhoven, Ronald F
collection PubMed
description
format Online
Article
Text
id pubmed-10359557
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher BMJ Publishing Group
record_format MEDLINE/PubMed
spelling pubmed-103595572023-07-22 Correspondence on “Associations of baseline use of biologic or targeted synthetic DMARDs with COVID-19 severity in rheumatoid arthritis: results from the COVID-19 global rheumatology alliance physician registry” van Vollenhoven, Ronald F Tas, Sander W Nurmohamed, Michael T Ann Rheum Dis Correspondence BMJ Publishing Group 2023-08 2021-08-13 /pmc/articles/PMC10359557/ /pubmed/34389606 http://dx.doi.org/10.1136/annrheumdis-2021-221146 Text en © Author(s) (or their employer(s)) 2023. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ. https://creativecommons.org/licenses/by-nc/4.0/This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/ (https://creativecommons.org/licenses/by-nc/4.0/) .
spellingShingle Correspondence
van Vollenhoven, Ronald F
Tas, Sander W
Nurmohamed, Michael T
Correspondence on “Associations of baseline use of biologic or targeted synthetic DMARDs with COVID-19 severity in rheumatoid arthritis: results from the COVID-19 global rheumatology alliance physician registry”
title Correspondence on “Associations of baseline use of biologic or targeted synthetic DMARDs with COVID-19 severity in rheumatoid arthritis: results from the COVID-19 global rheumatology alliance physician registry”
title_full Correspondence on “Associations of baseline use of biologic or targeted synthetic DMARDs with COVID-19 severity in rheumatoid arthritis: results from the COVID-19 global rheumatology alliance physician registry”
title_fullStr Correspondence on “Associations of baseline use of biologic or targeted synthetic DMARDs with COVID-19 severity in rheumatoid arthritis: results from the COVID-19 global rheumatology alliance physician registry”
title_full_unstemmed Correspondence on “Associations of baseline use of biologic or targeted synthetic DMARDs with COVID-19 severity in rheumatoid arthritis: results from the COVID-19 global rheumatology alliance physician registry”
title_short Correspondence on “Associations of baseline use of biologic or targeted synthetic DMARDs with COVID-19 severity in rheumatoid arthritis: results from the COVID-19 global rheumatology alliance physician registry”
title_sort correspondence on “associations of baseline use of biologic or targeted synthetic dmards with covid-19 severity in rheumatoid arthritis: results from the covid-19 global rheumatology alliance physician registry”
topic Correspondence
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10359557/
https://www.ncbi.nlm.nih.gov/pubmed/34389606
http://dx.doi.org/10.1136/annrheumdis-2021-221146
work_keys_str_mv AT vanvollenhovenronaldf correspondenceonassociationsofbaselineuseofbiologicortargetedsyntheticdmardswithcovid19severityinrheumatoidarthritisresultsfromthecovid19globalrheumatologyalliancephysicianregistry
AT tassanderw correspondenceonassociationsofbaselineuseofbiologicortargetedsyntheticdmardswithcovid19severityinrheumatoidarthritisresultsfromthecovid19globalrheumatologyalliancephysicianregistry
AT nurmohamedmichaelt correspondenceonassociationsofbaselineuseofbiologicortargetedsyntheticdmardswithcovid19severityinrheumatoidarthritisresultsfromthecovid19globalrheumatologyalliancephysicianregistry

Ejemplares similares